Table 1 Characteristics of 50 breast cancer tumors were analyzed in this study. *Two patients with two different subtype tumors; **two patients (three tumors) without information about TNM, G status; ***HER2: 2+ FISH (fluorescence in situ hybridization) negative; TNBC = triple negative breast cancer; HER2 = humane epithelial growth receptor 2 positive breast cancer; yr = year; ER = estrogen receptor; PR = progesterone receptor; Luminal B (estrogen receptors (ER+) and/or progesterone receptors (PR+)) with ki67 > 14%)
Variable | TNBC *** | HER2+ | Luminal B | Total (BC) |
|---|---|---|---|---|
(n = 23) | (n = 6) | (n = 21) | (n = 50)* | |
Mean age – (yr) | 53 | 53.7 | 50 | 52.1 |
Sex - no. (%) | ||||
Male | 0 | 0 | 0 | 0 |
Female | 23 (100) | 6 (100) | 21 (100) | 48 (100)* |
N stage positive (%) | 10 (45.5) ** | 3 (50.0) | 10 (52.6)** | 23 (45.1)** |
M0 / Mx (%) | 22 (100) ** | 6 (100) | 19 (100)** | 45 (100)** |
T stage (%) | ||||
T1 | 3 (13.6) ** | 0 (0) | 3 (15.8)** | 6 (13.3)** |
T2 | 18 (81.8) ** | 5 (83.3) | 11 (57.9)** | 33 (73.3)** |
T3 | 1 (4.5) ** | 1 (16.7) | 3 (15.8)** | 5 (11.1)** |
T4 | 0 (0) | 0 (0) | 2 (10.5)** | 2 (4.4)** |
Grade (%) | ||||
G2 | 13 (59,1) ** | 5 (83.3) | 12 (63.2) ** | 29 (64.4)** |
G3 | 9 (40.9) ** | 1 (16.7) | 7 (36.8) ** | 17 (37.8)** |
Clinico-pathological markers | ||||
ER positive > 2 (%) | 0 (0) | 0 (0) | 21 (100) | 21 (43.8) |
PR positive > 1 (%) | 0 (0) | 0 (0) | 20 (95.2) | 20 (41.7) |
HER2neu Dako: 0 (%) | 16 (69.6) | 0 (0) | 5 (23.1) | 21 (43.8) |
HER2neu Dako: 1+ (%) | 6 (26.1) | 0 (0) | 6 (28.6) | 12 (25.0) |
HER2neu Dako: 2+/3+ (%) | 1 (4.3) *** | 6 (100) | 10 (43.5) | 15 (31.3) |
Ki67 (%) | 42.6 | 30.6 | 33.1 | 37.2 |